Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
  • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
  • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
  • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
  • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
  • A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
  • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
  • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
  • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
  • A61K8/9783—Angiosperms [Magnoliophyta]
  • A61K8/9789—Magnoliopsida [dicotyledons]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/16—Emollients or protectives, e.g. against radiation
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
  • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
  • A61Q19/004—Aftersun preparations
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
  • A61Q19/06—Preparations for care of the skin for countering cellulitis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
  • A61Q19/08—Anti-ageing preparations
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
  • A61K2236/10—Preparation or pretreatment of starting material
  • A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
  • A61K2236/30—Extraction of the material
  • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
  • A61K2236/30—Extraction of the material
  • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
  • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
  • A61K2236/30—Extraction of the material
  • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
  • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
  • A61K2236/30—Extraction of the material
  • A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
  • A61K2236/50—Methods involving additional extraction steps
  • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
  • A61K2236/50—Methods involving additional extraction steps
  • A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
  • A61K2236/50—Methods involving additional extraction steps
  • A61K2236/55—Liquid-liquid separation; Phase separation

Definitions

• the invention relates to an extract of passionflower seeds, Passiflora incarnata or edulis and preferably edulis, particularly rich in polyphenols and a process for the preparation of such an extract.
• the present invention also relates to the cosmetic, dermatological or therapeutic use of such a composition or of such an extract.
• the invention finally relates to a method of cosmetic care of the skin, superficial body growths or mucous membranes, comprising administering such a composition or such an extract.
• the passiflora family (Passiflora) consists of about 500 species. Species are often distributed in warm temperate and tropical regions, particularly in the Americas, but are rather rare in Asia, Australia and tropical Africa.
• Plants come in the form of shrubs or climbing grasses.
• the leaves are alternate, sometimes simple, lobed or webbed.
• the flowers can wait 9 cm in diameter, are bisexual or unisexual and regular. They are white and purple and have fine petaloid appendages, trimmed with filiform appendages symbolizing the crown of thorns of Christ.
• the fruit 4 to 5 cm long is oval and often yellow to orange.
• the most common species include Passiflora incarnata (P. incarnata) and Passiflora edulis (P. edulis).
• P. incarnata the major constituents are represented by the family of flavonoids that are present in large quantities in the leaves.
• the leaves contain, in particular, a high content of isovitexin.
• the leaves of P. incarnata also contain a small amount of simple indole alkaloids (harmane, harmine %), sugars such as raffinose, sucrose, fructose, glucose, and essential oils. and maltol described as the molecule that would be responsible for the sedative and anti-convulsive effects attributed to this plant.
• P. edulis from a methanolic extract of dried leaves, a specific compound has been identified: the passiflorin - cyclopropane triterpene glycoside (E. Bombardelli et al, 1975).
• the leaves of P. edulis contain in particular isoorientine, a flavonoid that is not found in the species P. incarnata. They also contain traces of essential oil and alkaloids identical to the P. incarnata species.
• the fruit pulp contains flavonoids, schaftoside, isoschaftoside, isoorientine, orientine, isovitexine, luteolin derivatives (MX Zeraik, J. H. Yariwake - 2010), ascorbic acid (about 60 mg / 100 g).
• the pulp also contains glycosylated cyanogenic derivatives: prunasin, sambunigrin and amygdalin, as well as two newly identified ⁇ -rutinoside mandelonitrile (Chassagne and Crouzet, D. 1998, D.S. Seigler, 2002).
• Cyanogenic constituents are present mainly in the aerial parts of different varieties of passionflower.
• the seeds constitute 6 to 12% of the fruit of P. Edulis and they contain:
• polyphenols including Piceatannol (a resveratrol-like structure) and scirpusin B dimer (S. Sano, K. Sugiyama, T. Ito, 2011), substances with vasorelaxant and antioxidant effects.
• phytosterols (0.2%> including campesterol, stigmasterol, sitosterol, avenasterol); 60 to 73% o of linoleic acid (omega 6), 14%> to 20%> of oleic acid and 465 ppm of tocopherols (Piobom G., N. Barou et al, 2006, R. of VV Lopes et al. ).
• Passiflora (often aerial parts and sometimes fruit) are often used all over the world as anxiolytic, sedative, diuretic or analgesic ("Passiflora: review update, K. Dhawan, S. Dhawan, A. Sharma, 2004"). Maltol and some of its derivatives are at the origin of this sedative effect.
• Extracts of P. incarnata would be able to fight against addiction to morphine.
• MMP2 and MMP9 matrix metalloproteinases
• leaves of P. foetida are used topically to treat skin diseases of inflammatory origin, particularly through the presence of isoorientine.
• leaf decoctions of P. suberosa are also used in baths to treat skin diseases.
• the subject of the invention is thus a polyphenolic extract of Passionflower seeds, in particular seeds of Passiflora incarnata or Passiflora edulis, more particularly of Passiflora edulis, comprising at least 30% by weight of polyphenols, expressed in gallic acid equivalent. , in relation to the weight of the extract dry. This content is equivalent to at least 3 mg of polyphenols per milliliter of liquid extract.
• the polyphenol content is expressed in gallic acid equivalent, relative to the weight of the dry extract. These percentages are obtained by a Folin-Ciocalteu assay.
• the Folin-Ciocalteu reagent (commercially available).
• the latter comprises a mixture of phosphotungstic acid (H3PW12O40) and phosphomolybdic acid (H3PMol2O40) which is reduced, during the oxidation of the phenolic substances, to a mixture of blue oxides of tungsten (W8023) and molybdenum (Mo8023).
• the blue color produced has a maximum absorption around 750-760 nm. It is proportional to the amount of oxidized phenolic compounds.
• the reference phenol used in this method is gallic acid (see, for example, SINGLETON et al., Colorimetry of total phenolics with phosphomolybdicphosphotungstic acid reagents).
• the results obtained by this assay are therefore expressed in "% by weight of polyphenols, expressed in gallic acid equivalent, relative to the total weight of the dry extract”.
• the polyphenol content is therefore an easily measurable parameter for the skilled person.
• the extract according to the present invention advantageously comprises at least 35% by weight of polyphenols, expressed as gallic acid equivalent, relative to the total weight of said solids, that is to say at least 3.5 mg of polyphenols. per milliliter of liquid extract.
• the extract according to the present invention more advantageously comprises at least 40% by weight of polyphenols, expressed as gallic acid equivalent, relative to the total weight of said solids, that is to say at least 4 mg of polyphenols. per ml of liquid extract.
• catechin derivatives there are mainly catechin derivatives.
• catechol derivatives are understood to mean flavoinoids of the catechol family, also known as catechol.
• the catechin derivatives are more particularly compounds of general formula (I) next :
• R 1 represents OH or a galloyl group of formula (II) below
• R 2 represents H or OH.
• the catechin derivatives are more particularly compounds of general formula (I) chosen from the group consisting of:
• the extract according to the invention advantageously comprises at least 20% by weight, in particular at least 24% by weight of catechin derivatives, expressed as gallic acid equivalent, relative to the weight of the dry extract.
• at least 50% by weight, in particular at least 60% by weight, of the polyphenols are catechin derivatives, expressed in gallic acid equivalent, relative to the weight of polyphenols in the polyphenols. 'dry extract.
• the extract according to the invention also comprises at least 10% by weight of organic acids, in particular of acetic acid, of malic acid, of citric acid or their mixtures, relative to the weight of the extract. dry.
• the extract according to the invention comprises at least 30% by weight of polyphenols, expressed in gallic acid equivalent, relative to the weight of the dry extract, and at least 10% by weight of organic acids, especially acetic acid, malic acid, citric acid or mixtures thereof, relative to the weight of the dry extract.
• the extract according to the invention has the advantage of being rich in organic acids, which gives it a strong antioxidant, anti-chelating and / or moisturizing activity.
• the extract according to the invention is advantageously obtained by solid / liquid extraction of passionflower seeds in a solvent chosen from water, glycerol, glycols, and mixtures thereof.
• the solvent is more particularly chosen from water / glycerol binary mixtures, water / glycol, and mixtures thereof, advantageously in a proportion of between 30 and 90%, in particular between 40 and 90%, preferably between 50% and
• the solvent used is chosen from water / glycerol or water / propanediol binary mixtures, in particular water / propanediol, more particularly water / 1,3-propanediol.
• the extract according to the invention advantageously contains, by weight, with respect to the dry extract obtained:
• the extract according to the invention does not include isoorientine, orientine, vitexine or isovitexine.
• the subject of the invention is also a process for the preparation of a polyphenol extract of passionflower, in particular of seeds of Passiflora incarnata or of Passiflora edulis, advantageously of Passiflora edulis, comprising at least 30% by weight of polyphenols, expressed in equivalent terms.
• gallic acid based on the weight of the dry extract, said process comprising at least one solid / liquid extraction step in a solvent selected from water, glycerols, glycols, and mixtures thereof.
• said process for preparing a polyphenolic extract of passionflower seeds according to the invention comprises the following successive stages: a) crushing of the seeds;
• step d) optionally drying the extract obtained in step d).
• the step a) of grinding the seeds can be carried out by methods known to those skilled in the art, in particular by means of a knife mill, a hammer mill, etc.
• step c) the solid / liquid extraction phase is preferably carried out at a temperature of between 20 ° C. and 90 ° C., in particular between 30 ° C. and 80 ° C., more particularly between 45 ° C. and 75 ° C, typically 70 ° C.
• the extraction time is advantageously between 30 minutes and 4 hours, in particular between 1 and 3 hours, advantageously it is about 2 hours.
• the extraction solvent used in step c) is chosen from water / glycerol / water / glycol binary mixtures and their mixtures, advantageously in a proportion of between 30 and 90%, in particular between 40 and 90%. preferably between 50% and 90%, more preferably between 60% and 80%, especially 70%, of glycerol and / or glycol in water.
• the extraction solvent is chosen from water / glycerol or water / propanediol binary mixtures, in particular water / propanediol, more particularly water / 1,3-propanediol.
• the passionflower seeds are delipidated.
• the crushed seeds Before being dispersed, the crushed seeds can be delipidated, in particular in ethanol.
• the elimination of lipids allows a better efficiency of the extraction and filtration steps. It is also and preferably possible to use cakes from these seeds, that is to say the residue from the prior extraction of the oil by solvent, for example supercritical C0 2 technique and preferably by mechanical pressing.
• Step d) of separation of the solid phase and the liquid phase is carried out by methods known to those skilled in the art, in particular by decantation, centrifugation and / or successive filtrations to perfect clarity and microbiological cleanliness.
• the polyphenolic extract according to the invention can be stabilized by the drying step e), by methods known to those skilled in the art.
• the drying step may, for example, be carried out in the presence of a support of the type, for example, maltodextrins or acacia fibers (Fibregum® company CNI).
• the support content typically varies in a ratio ranging from 0% to 80% of support relative to the percentage of dry matter obtained in the liquid form of the extract.
• the extract is preferably dried by lyophilization in order to obtain a final powder.
• the final powder advantageously comprises 30 to 70% by weight of dry matter of the extract, the 100% complement being the freeze-drying support. More advantageously the final powder comprises 50% dry matter from the extract and 50%) freeze-drying support.
• the starting raw material of the process according to the invention may be a cake of delipidated passionflower seeds, in particular by pressing.
• the polyphenolic extract according to the invention can be obtained according to the following method:
• the extract obtained by the process according to the invention advantageously comprises at least 35% by weight, more preferably at least 40% by weight, of polyphenols, expressed in gallic acid equivalent, relative to the weight of the dry extract.
• the extract obtained by the process according to the invention also comprises at least 10% by weight of organic acids, in particular of acetic acid, of malic acid, of citric acid or their mixtures, relative to the weight of the dry extract.
• the extract obtained by the process according to the invention comprises at least 20% by weight, in particular at least 24% by weight of catechin derivatives, expressed in gallic acid equivalent, relative to the weight of the dry extract.
• at least 50% by weight, in particular at least 60% by weight, of the polyphenols are catechol derivatives expressed in gallic acid equivalent, relative to the weight of polyphenols in the dry extract.
• the present invention therefore also relates to an extract of passionflower seeds, in particular seeds of Passiflora incarnata or Passiflora edulis, advantageously Passiflora edulis, obtainable by the process. mentioned above.
• an extract meets the specifications defined above concerning the extract according to the invention.
• extract according to the invention to designate the extract as such, as defined above, or the extract obtainable by the process according to the invention. invention as described above.
• the invention further relates to a composition
• a composition comprising a polyphenol-rich extract of passionflower seeds according to the invention, as active ingredient, and optionally a suitable excipient.
• the extract according to the invention is as defined in the above paragraphs relating to the extract as such and those relating to the extract obtainable by the process according to the invention.
• composition according to the invention advantageously comprises from 0.001 to 10% by weight, advantageously from 0.01 to 5% by weight, of said polyphenol extract of Passionflower seeds according to the invention, the weight of the extract being expressed as dry extract. , relative to the total weight of the composition.
• composition is advantageously cosmetic, pharmaceutical or dermatological.
• the said composition is preferably formulated to be administered externally.
• composition according to the invention may further comprise one or more other active ingredients.
• composition according to the invention can be formulated in the form of different preparations adapted for topical administration.
• topical compositions may especially be creams, emulsions, milks, ointments, lotions, oils, aqueous or hydro-alcoholic or glycolic solutions, powders, patches, sprays, shampoos, varnish or any other product for external application.
• composition according to the invention may further comprise at least one cosmetically, pharmaceutically or dermato logically acceptable excipient.
• the composition according to the present invention may further comprise at least one cosmetically, pharmaceutically or dermato adjuvant logically known to those skilled in the art, chosen from surfactants, thickeners, preservatives, perfumes, dyes, chemical or mineral filters, moisturizers, thermal waters, etc.
• surfactants chosen from surfactants, thickeners, preservatives, perfumes, dyes, chemical or mineral filters, moisturizers, thermal waters, etc.
• the modes of administration, the dosages and the optimal dosage forms of the compositions according to the invention can be determined according to the criteria generally taken into account in the establishment of a pharmaceutical, dermatological or cosmetic treatment adapted to a patient or an animal. , such as the age or body weight of the patient or animal, the severity of his general condition, the tolerance to treatment, the side effects noted, the type of skin.
• the subject of the invention is also an extract according to the invention or a composition according to the invention for its use for preventing and / or treating disorders or pathologies of the skin and / or mucous membranes and / or integuments, advantageously reactions inflammatory reactions, oxidation reactions, disorders related to radical attacks related or not to pollution, disorders of the barrier or homeostasis, aging, in particular chronological and / or actinic aging, of the skin and / or or mucous membranes and / or integuments.
• the subject of the invention is also an extract according to the invention or a composition according to the invention for its use for preventing and / or treating vascular disorders and / or adipose tissue alterations.
• the subject of the invention is also the use of an extract of seeds of passiflora according to the invention or of a composition according to the invention, for the manufacture of a cosmetic, pharmaceutical or dermatological composition for preventing and / or treating disorders or pathologies of the skin and / or mucous membranes and / or integuments, advantageously inflammatory reactions, oxidation reactions, disorders related to radical attacks related or not to pollution, disorders of the barrier or homeostasis, aging, in particular chronological and / or actinic aging, of the skin and / or mucous membranes and / or integuments.
• the subject of the invention is also the use of an extract of seeds of passiflora according to the invention or of a composition according to the invention, for the manufacture of a cosmetic, pharmaceutical or dermatological composition for preventing and / or treating vascular disorders and / or adipose tissue alterations.
• the invention further relates to a method for preventing and / or treating disorders or pathologies of the skin and / or mucous membranes and / or integuments, advantageously inflammatory reactions, oxidation reactions, disorders related to radical attacks linked or not to pollution, barrier or homeostasis disorders, aging, in particular chronological and / or actinic aging, of the skin and / or mucous membranes and / or integuments, including administration , especially the topical administration of an effective amount of a passive-leaved seed extract according to the invention or a composition according to the invention, to a subject in need thereof.
• the invention furthermore relates to a method for preventing and / or treating vascular disorders and / or adipose tissue disorders, comprising administering, in particular topical administration, an effective amount of a seed extract of passiflores according to the invention or a composition according to the invention, to a subject in need.
• composition or the extract according to the invention is intended for the prevention and / or treatment of inflammatory reactions, oxidation reactions, disorders related to radical attacks related to environmental stress, such as pollution, UV, cigarette, etc., disorders of the barrier or homeostasis, aging, in particular chronological and / or actinic aging, of the skin, superficial body growths (hair and nails) and / or mucous membranes (gingiva, periodontitis, genital mucosa) immature, normal, mature or old.
• composition or the extract according to the invention is intended for the prevention and / or treatment of disorders related to inflammatory and / or radical reactions caused by UV exposures, and / or to pollutants, such as as heavy metals, or intrinsic reactions, and thus causing accelerated aging, barrier disorders, vascular disorders, redness, etc.
• composition or the extract according to the invention is intended (e) to fight against aging of the skin, especially against chronological aging and / or actinic.
• the extract according to the invention is intended to be used as an anti-pollution cosmetic agent.
• Cosmetic anti-pollution agent is an agent that protects the skin and keratinous substances so as to prevent, attenuate and / or eliminate the disorders or pathologies generated by toxic gases such as ozone and organic compounds combustion residues.
• a cosmetic anti-pollution agent has in particular an antioxidant and antiradical activity.
• Pollution referred to here is in particular air pollution (such as ozone), outdoor pollutants (eg nitrogen oxides, carbon monoxide, sulfur dioxide, ammonia, volatile organic compounds such as polycyclic aromatic hydrocarbons (eg benzo-a-pyrene), indoor pollutants (eg volatile organic compounds, paint residues, biocontaminants, tobacco smoke, cooking smoke, building materials, household cleaning products or wood treatment products).
• outdoor pollutants eg nitrogen oxides, carbon monoxide, sulfur dioxide, ammonia
• volatile organic compounds such as polycyclic aromatic hydrocarbons (eg benzo-a-pyrene)
• indoor pollutants eg volatile organic compounds, paint residues, biocontaminants, tobacco smoke, cooking smoke, building materials, household cleaning products or wood treatment products.
• disorders or pathologies of the skin mentioned above are more particularly vascular disorders, atopic dermatitis, eczema, irritative dermatitis, sensitive skin, reactive skin, skin with redness, erythema dermal, aged or photoaged skin, photosensitized skin, sunburns and inflammations due to rays of all kinds.
• the invention also relates to a process for the cosmetic care of the skin and / or superficial body growths and / or mucous membranes, with a view to improving their state and / or their appearance, consisting in administering a composition or an extract according to the present invention, advantageously by external topical route.
• the invention relates to a method for the cosmetic care of the skin, with a view to preventing aging, comprising applying to the skin a composition or an extract according to the present invention.
• the invention also relates to a cosmetic treatment method intended to obtain a protection of the organism against the effects of pollution, consisting in applying to the skin and the integuments, an extract or a composition according to the invention, especially in a quantity cosmetically effective.
• a cosmetic treatment method intended to obtain a protection of the organism against the effects of pollution, consisting in applying to the skin and the integuments, an extract or a composition according to the invention, especially in a quantity cosmetically effective.
• Figure 1 shows the percentage activation of NrF2 by an extract according to the invention.
• FIG. 1 shows Immunolabeling of Claudine 4 in BaP-treated skin explants (Protocol 1)
• FIG 3 shows Immunolabeling of fibaggrin in skin explants treated with BaP + Nicotine (Protocol 2)
• Figure 4 depicts Immunolabeling of loricrin in skin explants treated with BaP + Nicotine (Protocol 2)
• FIG. 5 shows Immunolabelling of Collagen I in skin explants treated with BaP + Nicotine (Protocol 2)
• FIG. 6 depicts Immunolabeling of Elastin in BaP-treated skin explants (Protocol 1)
• Figure 7 shows Immunolabelling of fibronectin in BaP-treated skin explants (Protocol 1)
• Figure 8 shows the comet visual appearance after electrophoresis of normal processed human keratinocytes.
• Figure 8A corresponds to a negative control sample
• Figure 8B to a UV control sample
• Figure 8C to an extract according to the invention to 0.001%.
• FIG. 9 shows the evolution of T0 and T28 heavy metal contents in the subjects studied.
• FIG. 10 represents the evolution of the MDA (FIG. 10A), Catalase and SOD (FIG. 10B) contents, expressed in U / mg of proteins, at T0 and at T28 in the subjects having received the placebo or having received the active
• Figure 11 shows the evolution of carbonyl protein content at T0 and T28 in placebo-treated or recipient-treated subjects.
• Figure 11A is in the form of a bar graph and
• Figure 11B shows photographs of cell layers with fluorescent labeling of carbonylated proteins. Quantification is then performed by image processing.
• a polyphenolic extract is obtained according to the following process:
• the liquid polyphenolic extract thus obtained has the following characteristics (% on Dry Extract):
• a polyphenolic extract is obtained according to the following process:
• the liquid polyphenolic extract thus obtained has the following characteristics (% on Dry Extract):
• the biological potential of an extract according to the invention was sought by means of a modulation test of gene expression on normal human fibroblasts (FHN) and on reconstructed and melanized human epidemics.
• RNAs were extracted and the gene expressions were analyzed by qRT-PCR using TaqMan map targeting key dermal and epidemic functions.
• polyphenols of the extract according to the invention have made it possible to modulate the gene expression of genes involved in the antioxidant defenses and the phenomenon of Hormesis (71 HMOX1, FTL and G6PD).
• the extract according to the invention has antioxidant, anti-radical and anti-aging activity.
• Hormetic molecule is a substance having a biphasic effect, which at low dose will have a beneficial effect but which at high dose will have the opposite effect (Ex: Prooxidant or Antioxidant). Hormetin is also described as a molecule reproducing the effects of a slight stress on the body but which in return will allow the cell to protect itself from future attacks and thus protect the body from various diseases (cancers) or phenomena age-related physical problems (skin aging, poor scarring ...) or harmful effects of the environment (UV, pollution ).
• HaCaT keratinocytes transfected ARE-Luciferase containing the plasmid Nqol Antioxidant Response Element (ARE) which is a plasmid specific for the activation of NrF2 and luciferase (reporter gene), were treated for 6 hours at 37 ° C. with an extract according to the invention, as obtained in Example 1, at concentrations ranging from 0.01% to 0.0005% (w / v) and by a positive reference Ter-butylhydroquinone at 20 ⁇ .
• ARE Nqol Antioxidant Response Element
• the cell mats are lysed, the luciferase activity is assayed using a "Luciferase Assay Kit” from PROMEGA and the protein content of each lysate is determined by the Bradford method (BioRad). Results and conclusion
• HMOX1, FTL, G6PD and Nrf2 the markers involved in cell detoxification
• SOD1 and Catalase the markers involved in cell detoxification
• the extract according to the invention has antioxidant, anti-radical and anti-aging activity.
• An extract according to the invention was analyzed on the protein expression of Heme Oxygenase.
• HMOX1 Heme Oxygenase 1
• HO1 Heme Oxygenase 1
• Nrf2 In order to verify whether the activation pathway of heme oxygenase by an extract according to the invention passes through an activation of Nrf2, the induction potential of the production of Heme Oxygenase has been verified in a system where the expression of Nrf2 is blocked (small siRNA interference).
• HMOX1 Heme Oxygenase 1
• results were analyzed statistically by a one-factor ANOVA followed by a Tukey test (GraphPad Prism Software version 5.02, GraphPad Software, San Diego California USA).
• the extract according to the invention has antioxidant, anti-radical and anti-aging activity.
• ERO E-Effect on the Production of Reactive Oxygen Species
• the extract according to the invention has antioxidant, anti-radical and anti-aging activity.
• the extract according to the invention for stimulating the defenses of the skin we evaluated their protective effect vis-à-vis various environmental stress, here pollution.
• the keratinocytes were then stimulated with Benzo- ⁇ -pyrene (BaP) at 9 ⁇ / ⁇ l for 20 minutes.
• BaP Benzo- ⁇ -pyrene
• the extract according to the invention has a protective effect vis-à-vis the oxidative stress induced by pollution.
• the extract according to the invention therefore has an antioxidant, anti-radical, anti-pollution and anti-aging activity.
• the extract according to the invention protected the following epidermal markers:
• the extract according to the invention therefore has antioxidant, anti-radical, anti-pollution and anti-aging activity.
• Reconstructed human epidemics were pretreated for 24 hours by topical application of a cosmetic formula containing or not (placebo) an extract according to the invention, as obtained in Example 1 at 3%.
• the epidemics were then subjected to ozone stress of 0.5 to 1 ppm.
• the enzymatic activities of the Catalase, Glutathione Peroxidase (GPX) and Superoxide Dismutase (SOD) detoxifying enzymes were quantified by ELISA in colorimetry (SOD and GPX) or fluorescence (Catalase).
• Lipid peroxidation was evaluated by the assay of MalonDiAldehyde (MDA), performed by CPG.
• MDA MalonDiAldehyde
• the oxidation of the DNA was evaluated by the assay of 8-HydroxydésoxyGuanosine (8-OHdG), made by colorimetry.
• results were analyzed statistically by a one-factor ANOVA followed by a Tukey test (GraphPad Prism Software version 5.02, GraphPad Software, San Diego California USA).
• the extract according to the invention induces no inhibition of the activity of the detoxifying enzymes. This confirms that it is indeed a protective effect vis-à-vis the induced stress and not an inhibition of cell detoxification systems.
• Ozone stress has induced oxidative damage that results in an increase in 8-OHdG and MDA.
• the extract according to the invention significantly protects the cellular elements of oxidative damage induced by ozone stress by significantly inhibiting the production of 8-OHdg and MDA.
• UV and IR penetrate more or less deeply into the skin and are responsible, among other things, for a decrease in its firmness and an increase in the amount of free radicals released resulting in premature cutaneous aging. . They are also responsible for melanoma formation and immunodepression of the skin.
• Cornet Assay is performed according to the method described by "Singh and al” in 1988 and by “De Meo et al” in 1991, which consists in irradiating the cells with light at 4.5 J / cm 2 (0, 28J / cm 2 of UVA, 0.08 J / cm 2 of UVB and 4.14 J / cm 2 of visible light) corresponding to an exposure of 1 to 3 min to the sun in summer. Then an electrophoretic gel migration of agarose DNA on a gel.
• a relative value of ⁇ 2 OTM is calculated using the software "Systat Software", the latter being directly proportional to the size of the comet and thus the degree of protection of the asset vis-à-vis the UV.
• the extract according to the invention therefore has antioxidant, anti-radical, antipollution and anti-aging activity.
• Table 15 Percentage of cell protection against UV
• IR Infrared
• Fibroblast Human Normal were incubated in the presence of an extract according to the invention as obtained in Example 1, 0.001% or dexamethasone with 10 "7 M (antiinflammatory reference) for 48 h following irradiation of 1 h by infrared (0.57 kJ / cm 2 ).
• the extract according to the invention therefore has antioxidant, anti-radical, antipollution and anti-aging activity.
• Extract according to the invention at 0.001% 77.4 14
• the keratinocytes were then stimulated by UVs at 2400J / m 2 (2000J / m 2 in UVB and 400J / m 2 in UVA) and then cultured in the presence of an extract according to the invention, as obtained in Example 1 at 0.001% and 0.005% (w / v) or vitamin C at 500 ⁇ for 15min at 37 ° C.
• ERO Active Oxygen Species
• results were analyzed statistically by a one-factor ANOVA followed by a Tukey test (GraphPad Prism Software version 5.02, GraphPad Software, San Diego California USA).
• the extract according to the invention significantly inhibited the production of ERO by keratinocytes in response to UV-induced oxidative stress at 2400J / m 2 (Table 17).
• PGE2 Prostaglandin E2
• Results The results are shown in Table 18. These results show that the extract according to the invention at both concentrations significantly decreased the release of PGE2 from PMA induction at 0.1 g / ml. .
• the extract according to the invention therefore has antioxidant, anti-radical, antipollution and anti-aging activity.
• An extract according to the invention was analyzed on a model of cellular aging in order to analyze their actions with respect to proteins which are under-expressed or overexpressed with age.
• Keratinocytes are cultured, and trypsinated every week, for 4 weeks in a culture medium inducing an aging phenotype (medium "Pro-age") in the presence or absence of an extract according to the invention, as obtained in Example 1, at 0.000025% of MS.
• Peroxiredoxin 2 an antioxidant enzyme that plays a role in cellular protection against damage caused by intracellular EROs.
• CBR1 Carbonyl Reductase 1
• dehydrogenase / reductase to reduce carbonyl compounds (drugs) and intervenes in detoxification during lipid peroxidation. This is inhibited under "pro-age” conditions and stimulated by the extract according to the invention under these conditions.
• Aldehyde Dehydrogenase 2 a mitochondrial enzyme that plays a role in cell protection and differentiation that will catalyze / detoxify aldehyde / carbonyl molecules (drugs, pollution ). This protein is stimulated under "pro-age” conditions, the extract according to the invention restores its level of expression to a basal level.
• Fatty Acid Binding Protein 5 (FABP5): Chaperone protein mainly expressed in the epidemic and involved in the regulation of lipid homeostasis and thus playing a role in the barrier function. The "pro-age” conditions inhibit its expression, which is restored by the polyphenols of Maracuja.
• Proteasome is involved in the removal of altered / oxidized proteins and in the renewal of intracellular proteins. It consists of subunits a and ⁇ which will, among other things, cut the altered proteins at the level of glutamine ( ⁇ 6) and trypsin level ( ⁇ 2). Age decreases the activity of Proteasome which leads to an accumulation of altered / oxidized proteins; this effect of age is found under the conditions "progeny" and under these conditions the extract according to the invention stimulates the expression of these two subunits of the proteasome.
• Beta-2-microglobulin a small surface protein (epidemic) involved in the immune response. It is part of the major histocompatibility complex and is overexpressed in pathological conditions which will induce the production of interleukins, in particular 6 and 8, as well as 10 which is an immunosuppressive interleukin. Here, under conditions inducing aging, its expression is increased. The extract according to the invention prevents this increase.
• LMAN1 Lectin Inhibition, mannose-binding, 1
• Pro-Age Protein 0.000025% "Pro-Age” 0.000025%
• Two groups of 30 subjects (1 Active group and 1 Placebo group), female, between 30 and 50 years old, Asians, all skin types, living in a polluted environment.
• the active ingredient makes it possible to replace the natural defenses of the skin, SOD and CAT, thus leading to a smaller amount of residues resulting from the process of detoxification (MDA).
• the polyphenol extract of passionflower seeds can be incorporated into various cosmetic products, such as cleaning waters, oil-in-water emulsions, water-in-oil emulsions, oils, milks, lotions, shampoos, foaming products and sprays, the compositions of which are given below as examples.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Epidemiology (AREA)
• Dermatology (AREA)
• Pharmacology & Pharmacy (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Natural Medicines & Medicinal Plants (AREA)
• Birds (AREA)
• Mycology (AREA)
• Microbiology (AREA)
• Botany (AREA)
• Biotechnology (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Alternative & Traditional Medicine (AREA)
• Medical Informatics (AREA)
• Gerontology & Geriatric Medicine (AREA)
• Emergency Medicine (AREA)
• Toxicology (AREA)
• Pain & Pain Management (AREA)
• Rheumatology (AREA)
• Medicines Containing Plant Substances (AREA)
• Cosmetics (AREA)

Priority Applications (7)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=55361825

Family Applications (1)

Country Status (8)

Cited By (2)

Families Citing this family (6)

Citations (2)

Family Cites Families (7)

• 2015
  • 2015-12-21 FR FR1562949A patent/FR3045380B1/fr active Active
• 2016
  • 2016-12-21 ES ES16812977T patent/ES2961703T3/es active Active
  • 2016-12-21 KR KR1020187020626A patent/KR102854323B1/ko active Active
  • 2016-12-21 EP EP16812977.3A patent/EP3393444B1/fr active Active
  • 2016-12-21 WO PCT/EP2016/082216 patent/WO2017108978A1/fr not_active Ceased
  • 2016-12-21 JP JP2018532411A patent/JP6907211B2/ja active Active
  • 2016-12-21 US US16/064,312 patent/US20190000902A1/en not_active Abandoned
  • 2016-12-21 CN CN201680081825.8A patent/CN108697610A/zh active Pending
• 2021
  • 2021-04-23 US US17/239,042 patent/US11596662B2/en active Active

Patent Citations (2)

Non-Patent Citations (4)

Also Published As

Similar Documents

Legal Events